



June 25, 2021

The Manager – Listing Department
National Stock Exchange of India Limited
Exchange Plaza, 5th Floor,
Bandra-Kurla-Complex,
Bandra (East), Mumbai - 400 051
NSE symbol: IDFC

The Manager – Listing Department
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001
BSE Scrip Code: 532659

Dear Sir/Madam,

Sub: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed copies of notice for the attention of equity shareholders of the Company in respect of transfer of Dividend and equity shares to Investor Education and Protection Fund (IEPF) Suspense Account published on June 25, 2021 in the Hindu Business Line and Makkal Kural read with Rule 6 of the Investor Education and Protection Fund Authority (Accounting, Audit, Transfer and Refund) Rules, 2016.

The advertisement copies will also be made available on the Company's website at the following web link: http://www.idfc.com/investor_relations/shareholder_info.htm

This is for your information and record.

Thanking you,

Yours faithfully,
For IDFC Limited

Mahendra N. Shah
Company Secretary & Compliance Officer

IIFCL bets big on ‘takeout’ to drive growth this year

‘To be largely aided by hybrid annuity model projects getting completed’

K.R.SRIVATS

New Delhi, June 24

India Infrastructure Finance Company Ltd (IIFCL), a government owned infrastructure lender, has decided to revise its strategy and place more emphasis on government sponsored projects and takeover financing this year, PR Jaishankar, Managing Director has said.

Aided by the hybrid annuity model (HAM) projects – largely seen in roads sector, IIFCL is looking to ramp up its takeover financing book to about ₹11,000 crore by end of this fiscal from the current level of ₹6,400 crore, Jaishankar told *BusinessLine*.

HAM projects

“We expect HAM projects to help us in a big way in achieving growth in takeover financing. 35-40 per cent of HAM projects are getting completed this year. We are already a leader in the HAM segment with 65 HAM projects financed by us. The projects that are already with me, I just have to take additional exposure of 10 per cent,” he said.

Under Takeout financing, loans made by banks to infrastructure firms are sold to IIFCL so that banks recover their much needed funds ahead of the payment schedule under the loan agreement. The scheme offers infrastructure developers the



PR Jaishankar, MD, IIFCL

benefit of lower interest rates than that under direct lending, freeing up their exposure limits with banks.

So far, IIFCL has been largely focused on institutional and refinancing solutions to drive growth.

For the current fiscal, IIFCL is eyeing sanctions in excess of ₹20,892 crore, which was the sanctions level achieved in 2020-21 and the highest ever sanctions recorded by the company. IIFCL would aim to reach disbursement level of over ₹12,000 crore, much higher than the disbursement level of ₹9,460 crore in 2020-21, according to Jaishankar.

KERALA BOOKS AND PUBLICATIONS SOCIETY
(An undertaking of the Government of Kerala)
KAKKANAD P.O.
KOCHI 682 030. KERALA
Website : www.keralabooks.org
E-mail : books.kbps@gmail.com

P2-3426/LT/DIST/2021/1760 Dated: 11.06.2021

Re-tender Notice
Re e-tenders are invited from goods transport vehicle owners for the Transportation of Lottery Tickets from KBPS to the Directorate of State Lotteries at Vikas Bhavan, Thiruvananthapuram and Various District Lottery offices in Kerala. For more details, please contact over ph: 0484-2422343, 9995412786, 9995416786 or visit our web site www.keralabooks.org.

Sd/- Managing Director

Meanwhile, Jaishankar said that IIFCL is awaiting Reserve Bank of India (RBI) approval for it to invest in several Infrastructure Investment Trusts (InvITs) that have taken off in the country.

Awaiting nod

“If RBI clarifies and allow us to invest in InvITs, then this will be another big revenue stream for us and add another ₹4,000 crore in the days to come.

“Like any other bank, we also want to offer financial assistance to InvITs. How we have to do it, whether we have to invest in the form of security or we have to lend directly at the SPV level, that is something we will look into. I am very hopeful that RBI will consider us favourably”, Jaishankar said.

Kapol Co-op Bank takes first step towards merger with Pune’s Cosmos

Special general body meeting okays resolution

KRAM KUMAR

Mumbai, June 24

Action is rising in the urban co-operative banking (UCB) space, with Mumbai-based Kapol Co-operative Bank taking its first step towards an amalgamation with Pune-based Cosmos Co-operative Bank.

The special general body meeting of the Kapol Co-operative Bank unanimously voted on the resolution “to consider and approve merger of the Bank with The Cosmos Co-operative Bank Ltd” on June 9, 2021.

The aforementioned development came about nine days before the Reserve Bank of India (RBI) accorded its “in-principle” approval to Centrum Financial Services to set up a small finance bank (SFB), which in turn is expected



Kapol Bank was placed under Directions by the RBI in 2017

ted to take over the scam-hit Punjab & Maharashtra Co-operative (PMC) Bank.

‘Clear path available’

Jyotindra Mehta, President, The National Federation of Urban Co-operative Banks and Credit Societies, observed that the resolution of weak UCBs has brightened after the September 2020 amendment to the Banking Regulation (BR) Act, 1949, as an UCB can be merged with any bank, be it a SFB, universal bank or another UCB. “Now a clear path to resolution

via amalgamation is available,” Mehta said. The Kapol Co-operative Bank was placed under Directions by the RBI with effect from the close of business on March 30, 2017. Once an UCB is placed under Directions, deposit withdrawal is capped.

This brings a lot of misery to the depositors. An UCB under Directions also cannot grant or renew any loans and advances, make any investment, incur any liability, among others. While stressed UCBs are placed under Directions by RBI to nurse them back to health, many stay under Directions for years.

As per Kapol Co-operative Bank’s latest balance sheet, as at March-end 2020, it had deposits and advances aggregating ₹392 crore and ₹150 crore, respectively.

Cosmos Co-operative Bank had deposits and advances aggregating ₹15,95 crore and ₹11,503 crore, respectively, as at March-end 2020.

Triton Electric Vehicle to set up ₹2,100-cr unit in Telangana

Project expected to employ more than 25,000 persons

OUR BUREAU

Hyderabad, June 24

Triton Electric Vehicle Pvt Ltd has entered into a memorandum of understanding (MoU) with the Telangana government for setting up of a manufacturing unit for electric buses in Zaheerabad.

Principal Secretary Jayesh Ranjan and Triton Electric Vehicle Founder and CEO Himanshu B Patel signed the MoU today, according to a statement.

With an investment of ₹2,100 crore, Triton Electric Vehicle proposes to establish an ultra-modern electric vehicle manufacturing unit. The project expects to employ more than 25,000 persons and produce 50,000 vehicles over the first five years, including

semi-trucks, sedans, luxury SUVs, and rickshaws.

The Telangana government will provide the required land to the firm through TSIC at NIMZ Zaheerabad.

‘Favourite destination’

State Industries Minister Minister KT Rama Rao said, “Telangana is fast transforming into a favourite destination for the electric vehicle manufacturing sector. The government will extend support to Triton to acquire the necessary approvals for setting up their facility.”

The Minister assured the firm of extending various incentives applicable for a mega project under the guidelines.

Himanshu Patel said that the company is seeking to cater to the increasing demand for electric vehicles. “The company decided to set up in Telangana due to its attractive industrial policy,” he added.

APOLLO HOSPITALS ENTERPRISE LIMITED

Corporate Identity Number : L85110TN1979PLC008035

Regd. Office: No.19, Bishop Gardens, Raja Annamalaiapuram, Chennai - 600 028. Tamil Nadu

Tel.: +91 44-2829 0956, Fax: +91-44-2829 0956.

E-mail: investor.relations@apollohospitals.com, Website: www.apollohospitals.com

Extract of Statement of Audited Financial Results for the Three Months and Year Ended March 31, 2021

(Rs. in Lakhs, except per share data)

S No.	Particulars	Standalone					Consolidated				
		Three months ended 31/03/2021	Preceding Three months ended 31/12/2020	Corresponding Three months ended 31/03/2020	Year ended 31/03/2021	Previous year ended 31/03/2020	Three months ended 31/03/2021	Preceding Three months ended 31/12/2020	Corresponding Three months ended 31/03/2020	Year ended 31/03/2021	Previous year ended 31/03/2020
		Refer Note 4	Unaudited	Refer Note 4	Audited	Audited	Refer Note 4	Unaudited	Refer Note 4	Audited	Audited
1	Total Income from Operations (net)	2,42,081	2,36,794	2,57,138	9,17,119	9,80,534	2,88,840	2,76,535	2,92,638	10,60,500	11,27,377
2	Net Profit /(Loss) for the period (before Tax, Exceptional and/or Extraordinary Items)	17,690	15,530	11,123	18,581	51,801	21,236	18,534	8,534	16,082	45,869
3	Net Profit /(Loss) for the period (before Tax, after Exceptional and/or Extraordinary Items)	16,890	15,530	27,558	17,672	68,236	23,756	18,534	28,364	22,147	65,699
4	Net profit /(Loss) for the period after tax (after Exceptional and Extraordinary Items)	11,552	10,622	20,560	10,515	47,025	16,989	13,416	20,960	13,677	43,180
5	Total Comprehensive Income for the period [comprising Profit/(Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	11,650	10,555	20,611	9,957	47,100	19,059	13,385	21,404	15,210	43,120
6	Paid up Equity Share Capital (Face value of Rs.5/- each)	7,189	6,956	6,956	7,189	6,956	7,189	6,956	6,956	7,189	6,956
7	Other Equity				5,12,973	3,91,876				4,52,293	3,26,167
8	Earnings Per Share of Rs. 5/- each										
	Basic	*8.10	*7.64	*14.78	7.51	33.80	*11.77	*9.38	*15.77	10.74	32.70
	Diluted	*8.10	*7.64	*14.78	7.51	33.80	*11.77	*9.38	*15.77	10.74	32.70
	Debt Equity Ratio				0.44	0.82					
	Debt Service Coverage Ratio				0.93	2.92					
	Interest Service Coverage Ratio				3.16	4.27					
	Networth				5,14,380	3,85,550					
	Paid up Debt Capital				20,000	50,000					
	Debenture Redemption Reserve				5,000	12,500					
	Capital Redemption Reserve				600	600					

* Not Annualised

Notes:

- The above is an extract of the detailed format of financial results (both standalone and consolidated) for the three months and year ended March 31, 2021 filed with stock exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Financial Results are available on the stock exchange websites www.nseindia.com and www.bseindia.com and also the company's website www.apollohospitals.com.
- The standalone financial information of Apollo Hospitals Enterprise Limited (“the Company”) for the three months and year ended March 31, 2021 have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meetings held on June 22, 2021 and June 23, 2021 respectively. The statutory auditors, Deloitte Haskins & Sells LLP have expressed an unmodified review conclusion on the financial results for the three months ended March 31, 2021 and have expressed an unmodified audit opinion on the financial results for the year ended March 31, 2021. These standalone financial results have been extracted from the standalone financial information.
- The consolidated financial information of Apollo Hospitals Enterprise Limited (“the Company”) for the three months and year ended March 31, 2021 have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meetings held on June 22, 2021 and June 23, 2021 respectively. The statutory auditors, Deloitte Haskins & Sells LLP have expressed an unmodified review conclusion on the consolidated financial results for the three months ended March 31, 2021 and have expressed an unmodified audit opinion on the consolidated financial results for the year ended March 31, 2021. These consolidated financial results have been extracted from the consolidated financial information.
- The financial results (both standalone and consolidated) for the three months ended March 31, 2021 and March 31, 2020 are the balancing figures between the audited figures for the respective years ended on those dates and the unaudited year to date figures for the nine months ending December 31, 2020 and December 31, 2019 respectively, which were subject to limited review.
- For the items referred in sub-clauses (a), (b), (d) and (e) of the Regulation 52(4) of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015, the pertinent disclosures have been made to the Stock Exchanges (BSE and NSE) and can be accessed on the URL (www.bseindia.com and www.nseindia.com)
- The Scheme of Arrangement (‘the Scheme’) for transfer of front-end retail pharmacy business included in the standalone pharmacy segment (‘divestment business’) to Apollo Pharmacies Limited (‘APL’ or ‘Transferee Company’), a wholly owned subsidiary of Apollo Medicals Private Limited (‘AMPL’), for an overall cash consideration of Rs.52,780 lakhs was effective from September 1, 2020 (‘effective date’). Consequently, the retail pharmacy segment as presented in these financial results include transactions of the divestment business till the effective date. Post the disposal of the divestment business, the Company has identified Pharmacy Distribution as a new segment with effect from September 1, 2020. The Company thereafter has identified Healthcare and Pharmacy Distribution as its operating and reportable segments. Healthcare segment represents hospitals and hospital based pharmacies. Pharmacy distribution segment represents the business of procurement and distribution of pharmaceutical, fast moving consumer goods (FMCG) and private label products. The figures for the quarter and year ended March 31, 2021 are not comparable with the figures for the corresponding three months ended March 31, 2020 and the figures for the previous year ended March 31, 2020.
- The Board of Directors at their meeting held on June 23, 2021 have approved the proposal to undertake transfer of pharmacy distribution business including the online technology platform Apollo 24/7 on a slump sale basis and its shareholding in Apollo Medicals Private Limited to a wholly owned subsidiary for a proposed consideration of Rs. 121,000 Lakhs, subject to receipt of requisite approvals from its shareholders, secured creditors and regulatory approvals.
- The Company declared a dividend for the year ended March 31, 2021 of Rs.3/- (60%) per equity share of face value of Rs.5/- each subject to the approval of the members at the forthcoming Annual General Meeting of the Company.
- The Company obtained shareholders and creditors approval with the requisite majority for the proposed Scheme of Merger of the following wholly owned subsidiary companies with the Company and is awaiting formal approval from the Regional Director, Southern Region, Ministry of Corporate Affairs for approving the Scheme of Merger:
 - Apollo Home Healthcare (India) Limited and
 - Western Hospitals Corporation Private Limited
- Pursuant to the approval accorded by the members through Postal Ballot to raise equity proceeds upto a sum of Rs 150,000 lakhs, the Company completed a Qualified Institutional Equity (QIP) placement in January 2021, allotting an additional 46,59,498 equity shares at a price of Rs 2,511 per share (face value Rs 5/- each) aggregating to a sum of Rs 116,999.99 lakhs. The utilisation of the QIP Issue proceeds upto March 31, 2021 is as follows:

Particulars	- Amount in Rs. Lakhs
Fees paid to Lead Managers	- 1,071.37
Foreclosure of Debts	- 20,928.62
Balance amounts placed in mutual funds pending deployment as on 31st March 2021	- 95,000.00
- The Company completed the acquisition of an additional 50% stake in Apollo Multi Speciality Hospitals Ltd, Kolkata (‘AMHL’) and formerly Apollo Gleneagles Hospital Ltd, Kolkata) during April 2021. As a consequence, AMHL is now a 100% wholly owned subsidiary of the Company. No effect of this acquisition has been given in these financial results since the acquisition was consummated post March 31, 2021
- Standalone :

Exceptional items represent provision for impairment of equity investment of Rs.800 lakhs held in an associate, Stemcyte Therapeutics India Private Limited in view of adverse business conditions.

Consolidated :

Exceptional items represent:

 - Impairment of the carrying value of investment of Rs.450 lakhs held in an associate, Stemcyte Therapeutics India Private Limited in view of adverse business conditions
 - Profit on sale of a nursing school of Rs. 466 lakhs earned by a subsidiary, Assam Hospitals Limited
- The Management has considered the possible effects if any that may result from the pandemic relating to COVID-19 on recoverability of receivables, Property, plant & equipment including Capital work in progress and certain investments. The Company has considered internal and external information up to the date of approval of these financial results. Based on the current indicators of future economic conditions, the Company expects to recover the carrying amount of these assets. The actual outcome of these assumptions and estimates may vary in future due to the impact of the pandemic. The Company will continue to monitor any material changes to future economic conditions and the consequent impact on its business, if any, and any significant impact of these changes would be recognized in the financial results as and when these material changes to economic conditions arise.
- The listed non-convertible debentures of the Company aggregating to Rs. 20,000 lakhs as at March 31, 2021 are secured by way of a charge of the Company’s properties and the asset cover thereof exceeds hundred percent of the principal amount of the said debentures.
- The Company’s debt instruments were assigned a rating of AA/Stable by CRISIL indicating high degree of safety.
- Consequent to the acquisition of additional 1% stake in Medics International Lifesciences Limited (‘Medics’) on 7th January 2021, Medics, an erstwhile joint venture, became a subsidiary of the Company with effect from the said date and the acquisition date fair value of the existing equity interest in Medics compared to its carrying amount resulted in a gain of Rs. 2,505 lakhs, which has been included under exceptional items. Further goodwill of Rs. 3,718 lakhs arising on this acquisition has also been recognised in the consolidated financial results.
- The proceedings initiated against Imperial Hospitals and Research Centre Limited, a subsidiary company, by the Government of Karnataka alleging, non-compliance of certain conditions associated with the allotment of land, has been stayed by the Honourable High Court of Karnataka on April 27, 2018. Based on legal opinion, the management is of the opinion that it has adequate grounds to demonstrate compliance with applicable conditions and therefore the proceedings are not sustainable. There have been no further developments during this quarter.
- The Company had made relevant disclosures to stock exchanges on 30th April 2021 and 15th May 2021 under SEBI Circular dated November 26, 2018 as applicable to Large Corporate Borrowers.

for APOLLO HOSPITALS ENTERPRISE LIMITED

Place : Chennai
Date : 23rd June 2021DR. PRATHAP C REDDY
Executive Chairman

Western Coalfields Limited
(A Subsidiary of Coal India Limited)

COMMON WINDOW ADVERTISEMENT - All the tenders issued by WCL for procurement of Goods, Works and Services are available on website of Coal India Limited www.coalindia.in respective subsidiary Company, CIL e-procurement portal <http://coalindiatenders.nic.in> and Central Public Procurement Portal <https://eprocure.gov.in>. In addition, procurement is also done through GeM Portal <https://gem.gov.in> - informs the G.M.(MM)HOD, WCL, Coal Estate, Civil Lines, Nagpur (M.S.). PIN: 440001.

GENERAL NOTICE - Tenders of WCL HQ / Areas are available at: (i) www.coalindiatenders.nic.in, (ii) www.eprocure.gov.in. Bids can be submitted on line through www.coalindiatenders.nic.in only. Corrigendum/Addendum, if any, are published in www.coalindiatenders.nic.in only - informs the General Manager (CMC), WCL HQ, Coal Estate, Civil Lines, Nagpur - 440001.

"Give a missed call on toll free number 18002003004 to get our apps"

I D F C

IDFC Limited

CIN : L65191TN1997PLC037415

Regd Office: 4th Floor, Capitale Tower, 555 Anna Salai, Thiru Vi Ka Kudiyruppu, Neynampet Chennai - 600018

Corp. Office: 906/907, 9th Floor, Embassy Centre, Jamnalal Bajaj Road, Nariman Point, Mumbai - 400021. Phone No.:+91 (22) 4222 2000, Fax No.:+91(22) 2654 0354, Email ID: info@idfc.com, Website: www.idfclimited.com

SUB: TRANSFER OF UNCLAIMED DIVIDEND FOR THE FINANCIAL YEAR 2013-14 AND THE UNDERLYING EQUITY SHARES OF IDFC LIMITED TO THE INVESTOR EDUCATION AND PROTECTION FUND (IEPF)

REF: SECTION 125 OF THE COMPANIES ACT, 2013 AND THE INVESTOR EDUCATION AND PROTECTION FUND (IEPF) AUTHORITY (ACCOUNTING, AUDIT, TRANSFER & REFUND) RULES, 2016 (the Rules).

Notice is hereby given to the shareholders of IDFC Limited (‘IDFC’ or ‘the Company’) that in terms of the relevant provisions of Section 125 of the Companies Act, 2013 and the Rules made thereunder, the unclaimed dividend for the financial year 2013-14 and the underlying equity share(s) of the Company, in respect of the said financial year (in case where the dividends for all the subsequent financial years have not been claimed by the concerned shareholder), are liable to be transferred by the Company to the IEPF Authority, in accordance with the Rules.

In terms of the Rules, the concerned shareholders who have not claimed their dividend(s) for seven consecutive years i.e. from financial year 2013-14 up to financial year 2020-21, are being provided an opportunity to claim their dividends, and are as such requested to write to KFin Technologies Private Limited (KFin), Registrar & Share Transfer Agent (RTA) of the Company, at the address mentioned below and send the undertaking duly filled and signed along with a self-attested copy of the PAN card, copy of address proof, a cancelled cheque, so as to reach KFin **on or before September 2, 2021**, failing which the Company will proceed to transfer the unclaimed dividend for the financial year 2013-14 and the underlying share(s) of the Company in respect of the said dividend registered in the name of the concerned shareholder(s), to the IEPF Authority, on or after the due date of **September 2, 2021** in accordance with the IEPF Rules 2016 as notified by the Ministry of Corporate Affairs effective September 7, 2016 and as amended from time to time.

The concerned shareholders, holding shares in physical form and whose shares are liable to be transferred to IEPF Authority, may please note that the Company would be issuing duplicate share certificate(s) in lieu of the original share certificate(s) and upon such issue, the original share certificate(s) registered in their name will automatically stand cancelled and be deemed non-negotiable. The Company shall then inform the depository by way of corporate action to convert the duplicate share certificate(s) into Demat form and transfer in favour of the Authority. For the shares held in Demat form, the Company shall inform the depository by way of corporate action where the shareholders have their accounts for transfer in favour of the Authority.

The Shareholders may further note that the details uploaded by the Company on its website should be regarded and shall be deemed to be adequate notice in respect of issue of the duplicate share certificate(s) by the Company for the purpose of transfer of shares to IEPF Suspend Account pursuant to the Rules. However, please note that once said unclaimed dividend/ equity shares are transferred to the IEPF Authority, it can be claimed by the concerned shareholder from the IEPF Authority, by following the procedures prescribed under the Rules.

Individual letters to the concerned shareholders, in this regard have already been sent to their registered address available with KFin. Details of the Shareholders whose unclaimed dividends and the underlying equity share(s) of the Company are due for transfer, as aforesaid, have been uploaded on the website of the Company i.e. on http://www.idfc.com/investor_relations/UnclaimedShares.htm

KFin Technologies Private Limited (IDFC Limited)
Karvy Selenium Tower B, Plot 31-32, Financial District, Nanakramguda, Serilingampally Mandal, Hyderabad - 500 032.
Tel No.: +9140-6716 2222 / 1800 345 4001 (toll free),
Fax No.: +9140-2300 1153, Email: enward.ris@kfintech.com

For IDFC Limited
Sd/-
Mahendra N Shah
Company Secretary & Compliance Officer

Place: Mumbai
Date: June 24, 2021

செ. ம. தொ. இ/476/வரைகலை/2021